Related Experiment Video
Updated: Jul 12, 2025
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
Heart failure with preserved ejection fraction: New challenges and new hopes
1Université Paris Cité, Inserm U942, Assistance publique hôpitaux de Paris, Hôpital Lariboisière, Paris, France.
Insights
Heart failure with preserved ejection fraction (HFpEF) affects millions globally. Recent advancements, including SGLT2 inhibitors and targeted therapies for obesity and inflammation, offer new hope for managing this complex condition.
Area of Science:
- Cardiology
- Internal Medicine
- Public Health
Background:
- Heart failure (HF) is a significant global health issue.
- HF with preserved ejection fraction (HFpEF), defined as ejection fraction > 50%, constitutes over half of all HF cases.
- Increasing prevalence of HFpEF is linked to population aging and metabolic disorders like obesity, diabetes, and hypertension.
Purpose of the Study:
- To review the complex pathophysiological mechanisms underlying HFpEF.
- To highlight recent therapeutic advancements in HFpEF management.
- To discuss the diagnostic challenges and evolving treatment landscape for HFpEF.
Main Methods:
- Literature review of recent studies and clinical trials on HFpEF.
- Analysis of diagnostic criteria including echocardiography, natriuretic peptides, and stress testing.
- Synthesis of evidence for emerging pharmacological interventions.
Main Results:
- HFpEF diagnosis is complex, often requiring multiple parameters.
- The SGLT2 inhibitor class has demonstrated significant efficacy in HFpEF.
- Emerging therapies targeting obesity and inflammation show promising results.
Conclusions:
- Understanding the intricate mechanisms of HFpEF is crucial for effective treatment.
- Recent therapeutic progress, particularly with SGLT2 inhibitors, offers new management strategies.
- Further research into targeted therapies for obesity and inflammation is warranted for HFpEF.
Abstract:
Heart failure (HF) is a major public health problem affecting millions of adults worldwide. HF with preserved ejection fraction, i.e. > 50 %, (HFpEF) accounts for more than half of all HF cases, and its incidence and prevalence are increasing with the aging of the population and the growing prevalence of metabolic disorders such as obesity, diabetes and hypertension. Diagnosis of HFpEF requires a combination of numerous echocardiographic parameters and also results of natriuretic peptide assays, to which may be added the need for a stress test. HFpEF is characterized by complex, interrelated pathophysiological mechanisms, which must be understood. This complexity probably accounts for the lack of evidence-based medicine compared with HF with reduced EF. Nevertheless, significant progress has been made recently, with a high level of evidence obtained for the SGLT2 inhibitor class on the one hand, and promising data with new drugs targeting more specifically certain mechanisms such as obesity and inflammation on the other.
Related Concept Videos
01:30Heart Failure IV: Classification and Diagnostic Evaluation
01:17Pathophysiology of Heart Failure
01:30Heart Failure V: Medical Management
01:29Heart Failure II: Pathophysiology
01:27Heart Failure I: Introduction
01:30Heart Failure VII: Nursing Interventions